Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
David SoergelChief Medical Officer | Madrigal PharmaceuticalsMDGL | Open-market sale10b5-1 plan | 06/01 | 06/01 | 1,042 sh | $495.74 | $516,561.08 | −9.4% |
Madrigal PharmaceuticalsMDGL | Open-market sale10b5-1 plan | 05/22 | 05/22 | 5,682 sh12 trades | $515.44avg. | $2,928,717.87 | −20.5% | |
David SoergelChief Medical Officer | Madrigal PharmaceuticalsMDGL | Open-market sale | 05/18 | 05/18 | 844 sh | $515.90 | $435,419.6 | −7.1% |
Rebecca TaubDirector | Madrigal PharmaceuticalsMDGL | Open-market sale | 03/06 | 03/06 | 491 sh | $431.94 | $212,082.54 | −0.1% |
William John SiboldPresident and CEO | Madrigal PharmaceuticalsMDGL | Open-market sale | 03/06 | 03/06 | 1,663 sh | $431.94 | $718,316.22 | −1.0% |
Madrigal PharmaceuticalsMDGL | Open-market sale10b5-1 plan | 03/06 | 03/06 | 1,982 sh12 trades | $430.87avg. | $853,992.6 | −13.7% | |
Carole HuntsmanChief Commercial Officer | Madrigal PharmaceuticalsMDGL | Open-market sale | 03/06 | 03/06 | 419 sh | $431.94 | $180,982.86 | −3.2% |
Shannon T. KelleyGeneral Counsel | Madrigal PharmaceuticalsMDGL | Open-market sale | 03/06 | 03/06 | 360 sh | $431.94 | $155,498.4 | −2.9% |
Mardi DierEVP and CFO | Madrigal PharmaceuticalsMDGL | Open-market sale | 03/02 | 03/02 | 1,183 sh | $427.21 | $505,389.43 | −11.3% |
Rebecca TaubDirector | Madrigal PharmaceuticalsMDGL | Open-market sale | 01/26 | 01/26 | 647 sh | $492.42 | $318,595.74 | −0.1% |
William John SiboldPresident and CEO | Madrigal PharmaceuticalsMDGL | Open-market sale | 01/26 | 01/26 | 1,577 sh | $492.42 | $776,546.34 | −1.1% |
Madrigal PharmaceuticalsMDGL | Open-market sale10b5-1 plan | 01/26 | 01/26 | 910 sh2 trades | $493.78avg. | $449,339.1 | −9.1% | |
Rebecca TaubDirector | Madrigal PharmaceuticalsMDGL | Open-market sale | 01/20 | 01/20 | 2,238 sh | $490.77 | $1,098,343.26 | −0.5% |
Madrigal PharmaceuticalsMDGL | Open-market sale10b5-1 plan | 01/20 | 01/20 | 692 sh2 trades | $497.36avg. | $344,173.11 | −7.5% | |
Madrigal PharmaceuticalsMDGL | Open-market sale10b5-1 plan | 01/09 | 01/13 | 24,800 sh29 trades | $522.71avg. | $12,963,319.78 | −11.7% | |
Madrigal PharmaceuticalsMDGL | Open-market sale10b5-1 plan | 01/09 | 01/13 | 18,650 sh30 trades | $522.76avg. | $9,749,384.66 | −3.9% | |
Madrigal PharmaceuticalsMDGL | Open-market sale10b5-1 plan | 25/12/10 | 25/12/12 | 24,800 sh9 trades | $552.18avg. | $13,694,142.6 | −11.7% | |
Madrigal PharmaceuticalsMDGL | Open-market sale10b5-1 plan | 25/12/10 | 25/12/12 | 18,650 sh9 trades | $552.15avg. | $10,297,601.5 | −3.9% | |
William John SiboldPresident and CEO | Madrigal PharmaceuticalsMDGL | Open-market sale | 25/12/04 | 25/12/04 | 2,400 sh | $575.34 | $1,380,816 | −1.6% |
Madrigal PharmaceuticalsMDGL | Open-market sale10b5-1 plan | 25/12/02 | 25/12/03 | 4,173 sh15 trades | $578.34avg. | $2,413,415.92 | −28.6% |